Connection

JAMES P ALLISON to Mice, Transgenic

This is a "connection" page, showing publications JAMES P ALLISON has written about Mice, Transgenic.
Connection Strength

0.868
  1. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol. 2015 Mar 01; 194(5):2089-98.
    View in: PubMed
    Score: 0.070
  2. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol. 2013 Jan 15; 190(2):526-30.
    View in: PubMed
    Score: 0.060
  3. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol. 2012 Aug 01; 189(3):1123-7.
    View in: PubMed
    Score: 0.058
  4. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol. 2012 Feb 01; 188(3):976-80.
    View in: PubMed
    Score: 0.056
  5. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med. 2010 Aug 02; 207(8):1701-11.
    View in: PubMed
    Score: 0.051
  6. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010 Mar 15; 207(3):637-50.
    View in: PubMed
    Score: 0.049
  7. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009 Aug 03; 206(8):1717-25.
    View in: PubMed
    Score: 0.047
  8. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008 Sep 01; 205(9):2125-38.
    View in: PubMed
    Score: 0.045
  9. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science. 2008 Jan 11; 319(5860):215-20.
    View in: PubMed
    Score: 0.043
  10. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 2006 Dec; 88(6):841-845.
    View in: PubMed
    Score: 0.039
  11. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006 Jul 15; 177(2):1052-61.
    View in: PubMed
    Score: 0.039
  12. Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
    View in: PubMed
    Score: 0.034
  13. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002 Jan; 16(1):23-35.
    View in: PubMed
    Score: 0.028
  14. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol. 2001 Nov; Chapter 20:20.5.1-20.5.23.
    View in: PubMed
    Score: 0.028
  15. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
    View in: PubMed
    Score: 0.024
  16. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
    View in: PubMed
    Score: 0.022
  17. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22; 94(15):8099-103.
    View in: PubMed
    Score: 0.021
  18. T cell-mediated elimination of B7.2 transgenic B cells. Immunity. 1997 Mar; 6(3):327-39.
    View in: PubMed
    Score: 0.020
  19. The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. Immunity. 1995 Oct; 3(4):439-47.
    View in: PubMed
    Score: 0.018
  20. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014 Jun 16; 25(6):719-34.
    View in: PubMed
    Score: 0.017
  21. Aire-dependent thymic development of tumor-associated regulatory T cells. Science. 2013 Mar 08; 339(6124):1219-24.
    View in: PubMed
    Score: 0.015
  22. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol. 2012 Oct 15; 189(8):4165-74.
    View in: PubMed
    Score: 0.015
  23. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-?1 cytokine. Immunity. 2011 Jul 22; 35(1):123-34.
    View in: PubMed
    Score: 0.014
  24. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14.
    View in: PubMed
    Score: 0.011
  25. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. J Immunol. 2005 Oct 01; 175(7):4199-207.
    View in: PubMed
    Score: 0.009
  26. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005 Feb 15; 174(4):1922-31.
    View in: PubMed
    Score: 0.009
  27. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173(10):6098-108.
    View in: PubMed
    Score: 0.009
  28. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol. 2004 Jan 01; 172(1):34-9.
    View in: PubMed
    Score: 0.008
  29. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8987-91.
    View in: PubMed
    Score: 0.004
  30. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. J Exp Med. 1993 Apr 01; 177(4):1061-70.
    View in: PubMed
    Score: 0.004
  31. Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. Int Immunol. 1991 Apr; 3(4):385-93.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.